Supporting the safe use of CDB in skincare products using Derek Nexus

Cannabidiol (CBD) is gaining prominence as a sought-after ingredient in skincare and beauty formulations, thanks to its notable anti-inflammatory, antioxidant and anti-bacterial properties. Derived directly from the hemp plant, this compound is increasingly being used as an ingredient in skincare products, particularly for the management of various skin conditions like eczema, dermatitis and psoriasis. Despite …

Supporting the safe use of CDB in skincare products using Derek Nexus Read More »

Fostering cross-cultural connections through art

Life at Lhasa, Discuss / By Josh.Cosby

Diversity serves as a catalyst for innovation at Lhasa. We believe in cultivating a workplace culture that encourages collaboration, and empowers every individual to express themselves fully. Art has the power to promote a culture of creativity, self-expression and community playing an integral role in enriching the fabric of our environment. Serving as a powerful …

Fostering cross-cultural connections through art Read More »

Insights into the 2024 Science of Stability Conference

Discuss, Innovate / By Josh.Cosby

Following the success of the 2022 Science of Stability (SOS) Conference in Philadelphia, we’re excited to announce its return to Barcelona! The 8th SOS will take place on the 13-14th May 2024, and we’re delighted to co-host it with FreeThink Technologies. With a focus on innovation and collaboration, this promises to be a milestone event …

Insights into the 2024 Science of Stability Conference Read More »

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways

Discuss, Innovate / By lara.james

We are delighted to share our important new open access article: In silico prediction of pharmaceutical degradation pathways: A benchmarking study using the software program Zeneth. The paper, recently published in Organic Process Research & Development (OPRD) is authored by Lhasa Principal Scientist Rachel Hemingway, alongside industry expert co-authors from AstraZeneca, GSK, Pfizer, BMS, Amgen …

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways Read More »

Mitigating the risks of NDSRI’s through data sharing

Innovate, Discuss / By Josh.Cosby

At Lhasa, we believe in the transformative power of knowledge sharing as the driving force to support the global challenge of nitrosamine risk assessment. Through data sharing and industry collaboration, we empower members to further understand the risks associated with their potential nitrosamine impurities. The Vitic Complex Nitrosamines initiative, launched in 2021 in response to …

Mitigating the risks of NDSRI’s through data sharing Read More »

Q&A deep dive with Martin Walter: How to establish AI limits for NDSRIs

Discuss / By emma.scrafton

Building on the success of our recent webinar, How to establish acceptable intake (AI) limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs), we’re thrilled to present a follow-up that brings you closer to the insightful discussions that unfolded during the interactive Q&A session. In this blog, we’ve gathered questions posed during the webinar and curated written …

Q&A deep dive with Martin Walter: How to establish AI limits for NDSRIs Read More »

Attendee insights from our Software Crafters Leeds meet-up

Life at Lhasa, Discuss / By Josh.Cosby

We were delighted by the incredible enthusiasm shown by participants at our Software Crafters Leeds event, co-hosted with Codurance. Exploring scientific software development bought together keen coders of all levels for a customised coding-dojo, demonstrating how software can be built to predict complex scientific outcomes. At Lhasa, we understand the significance of knowledge-sharing as a …

Attendee insights from our Software Crafters Leeds meet-up Read More »

Award winning paper paves path to more confident human safety assessments

Discuss / By Josh.Cosby

We are delighted to announce that our paper ‘Using adverse outcome pathways to contextualise (Q)SAR predictions for reproductive toxicity – A case study with aromatase inhibition’ has been selected as the best paper published in Reproductive Toxicology in 2022. The award winning-paper, authored by Lhasa Principal Scientist, Alun Myden, Senior Scientist, Emma White and Head …

Award winning paper paves path to more confident human safety assessments Read More »

Current status of the Ames test for N-nitrosamines

Discuss / By emma.scrafton

In our earlier instalments of the Lhasa blog, we have discussed the latest regulatory insights presented by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada regarding acceptable intake limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs). Now, our focus zeroes in on the Enhanced Ames Test (EAT) and its …

Current status of the Ames test for N-nitrosamines Read More »

What you need to know about the FDA’s new guidance on NDSRIs

Discuss / By emma.scrafton

The U.S. Food and Drug Administration (FDA) recently took a significant step forward in safeguarding public health by issuing a new guidance titled “Recommended Acceptable Intake Limits for Nitrosamine Drug Substance Related Impurities (NDSRIs) Guidance for Industry.” This important update addresses concerns related to NDSRIs, a group of nitrosamine impurities found in numerous drug products, …

What you need to know about the FDA’s new guidance on NDSRIs Read More »

Discuss

Supporting the safe use of CDB in skincare products using Derek Nexus

Fostering cross-cultural connections through art

Insights into the 2024 Science of Stability Conference

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways

Mitigating the risks of NDSRI’s through data sharing

Q&A deep dive with Martin Walter: How to establish AI limits for NDSRIs

Attendee insights from our Software Crafters Leeds meet-up

Award winning paper paves path to more confident human safety assessments

Current status of the Ames test for N-nitrosamines

What you need to know about the FDA’s new guidance on NDSRIs

Sign up to our newsletter

Connect with us